Small breast epithelial mucin tumor tissue expression is associated with increased risk of recurrence and death in triple-negative breast cancer patients

Diagnostic Pathology

Fulin Song³  Xiaodong Xie¹  Yongye Liu¹  Zhendong Zheng¹  Shuxian Qu¹  Zhaozhe Liu¹  Liang Liu² 

[1] Department of Oncology, Cancer Center of General Hospital of Shenyang Military Region, Shenyang 110840, China;Department of Oncology, Weifang People's Hospital, Weifang, 261041, China;Department of Pathology, General Hospital of Shenyang Military Region, Shenyang, 110840, China

关键词: TNBC;    IHC;    OS;    DFS;    SBEM;   

Others  :  807102
DOI  :  10.1186/1746-1596-8-71

 received in 2013-03-06, accepted in 2013-04-19,  发布年份 2013

【 摘 要 】

Background

Small breast epithelial mucin (SBEM) has been implicated in tumor genesis and micrometastasis in breast cancer. Triple-negative breast cancer (TNBC) was characterized by high incidence in young women,early relapse and a very poor prognosis. The aim of this study was to evaluate the association of SBEM expression in tissues of TNBC with disease-free survival (DFS) and overall survival (OS).

Methods

SBEM protein expression was detected in 87 available formalin-fixed paraffin-embedded (FFPE) tissue specimens from TNBC patients by means of immunohistochemistry (IHC). We analyzed the correlation between the SBEM protein expression and DFS and OS during a 5 year follow-up period, respectively. And a SBEM cut-off value of prognosis was established associated with DFS and OS. SBEM was analyzed against other risk factors in multivariate analysis.

Results

SBEM 3+ score was cut-off value of prognosis and significantly correlated with DFS (p = 0.000) and OS (p = 0.001) in TNBC patients. There was a marked associations (p <0.05) between SBEM 3+ score and tumor size, grade, node status, TNM stage and Ki67. Multivariate analysis showed that patients with SBEM 3+ represented a higher risk of recurrence and mortality than those with a lower SBEM expression (HR = 3.370 with p = 0.008 for DFS and HR = 4.185 with p = 0.004 for OS).

Conclusions

SBEM is an independent risk predictor and may offer utility as a prognostic marker in TNBC patients.

Virtual Slides

http://www.diagnosticpathology.diagnomx.eu/vs/1624613061936917 webcite

【 授权许可】

   
2013 Liu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumors. Nature 2000, 406:747-752.
• [2]Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
• [3]Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502.
• [4]Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008, 26:1275-1281.
• [5]Millar EK, Graham PH, O'Toole SA, McNeil CM, Browne L, Morey AL, Eggleton S, Beretov J, Theocharous C, Capp A, Nasser E, Kearsley JH, Delaney G, Papadatos G, Fox C, Sutherland RL: Prediction of local recurrence, distant metastases, and death after breast conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 2009, 27:4701-4708.
• [6]Knudson AG: Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001, 1(2):157-162.
• [7]Miksicek RJ, Myal Y, Watson PH, Walker C, Murphy LC, Leygue E: Identification of a novel breast-and salivary gland specific, mucin-like gene strongly expressed in normal and tumor human mammary epithelium. Cancer Res 2002, 62(10):2736-2740.
• [8]Skliris GP, Hubé F, Gheorghiu I, Mutawe MM, Penner C, Watson PH, Murphy LC, Leygue E, Myal Y: Expression of small breast epithelial mucin (SBEM) protein in tissue microarrays (TMAs) of primary invasive breast cancers. Histopathology 2008, 52(3):355-369.
• [9]Liu ZZ, Xie XD, Qu SX, Zheng ZD, Wang YK: Small breast epithelial mucin (SBEM) has the potential to be a marker for predicting hematogenous micrometastasis and response to neoadjuvant chemotherapy in breast cancer. Clin Exp Metastasis 2010, 27:251-259.
• [10]Valladares-Ayerbes M, Iglesias-Díaz P, Díaz-Prado S, Ayude D, Medina V, Haz M, Reboredo M, Antolín S, Calvo L, Antón-Aparicio LM: Diagnostic accuracy of small breast epithelial mucin mRNA as a marker for bone marrow micrometastasis in breast cancer: a pilot study. J Cancer Res Clin Oncol 2009, 135(9):1185-1195.
• [11]Jennbacken K, Vallbo C, Wang W, Damber JE: Expression of Vascular Endothelial Growth Factor C (VEGF-C) and VEGF Receptor-3 in human prostate cancer are associated with regional lymph node metastasis. Prostate 2005, 65(2):110-116.
• [12]Serrero G, Ioffe O: Expression of the novel autocrine growth factor PC-Cell Derived Growth Factor in human breast cancer tissue. Hum Pathol 2003, 34:1148-1154.
• [13]Pan AP, Huang GY, Chen J: Relationship between hepatitis B virus covalently closed circular DNA and HBx protein expression in hepatocellular carcinoma and its significance. World Chin J Digestol 2009, 17:712-715.
• [14]Serrero G, Hawkins DM, Yue B, Ioffe O, Bejarano P, Phillips JT, Head JF, Elliott RL, Tkaczuk KR, Godwin AK, Weaver J, Kim WE: Progranulin (GP88) tumor tissue expression is associated with increased risk of recurrence in breast cancer patients diagnosed with estrogen receptor positive invasive ductal carcinoma. Breast Cancer Res 2012, 14:R26. BioMed Central Full Text
• [15]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 2012, 62(1):10-29.
• [16]Wang Y, Zhu J-f, Liu Y-y, Han G-p: An analysis of Cyclin D1, Cytokeratin 5/6 and Cytokeratin 8/18 expression in breast papillomas and papillary carcinomas. Diagn Pathol 2013, 8:8. BioMed Central Full Text
• [17]Petra Barros Dos S, Zanetti JS, Alfredo R-S, Eduardo IC B: Beta integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study. Diagn Pathol 2012, 7:104. BioMed Central Full Text
• [18]Yao ES, Zhang H, Chen YY, Lee B, Chew K, Moore D, Park C: Increased beta1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res 2007, 67(2):659-664.
• [19]Dingemans AM, van den Boogaart V, Vosse BA, van Suylen RJ, Griffioen AW, Thijssen VL: Integrin expression profiling identifies integrin alpha 5 and beta 1 as prognostic factors in early stage non-small cell lung cancer. Mol Cancer 2010, 9(152):1-9.
• [20]Qingli Z, Qinghui Z, Hua C, Xiaoli Z: The ectopic expression of BRCA1 is associated with genesis, progression, and prognosis of breast cancer in young patients. Diagn Pathol 2012, 7:181. BioMed Central Full Text
• [21]Lux MP, Fasching PA, Beckmann MW: Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med (Berl) 2006, 84(1):16-28.
• [22]Hinde EI F, Sanae C, Sofia J, Kaoutar M, My Abdelilah M, Abdelaziz B, Omar M, Afaf A: Luminal B tumors are the most frequent molecular subtype in breast cancer of North African women: an immunohistochemical profilestudy from Morocco. Diagn Pathol 2012, 7:170. BioMed Central Full Text
• [23]Weigel MT, Dowsett M: Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer 2010, 17:R245-R262.
• [24]Xue Q, Qiliu P, Aiping Q, Zhiping C, Liwen L, Yan D, Li X, Juanjuan X, Haiwei L, Taijie L, Shan L, Jinmin Z: Association of COMT Val158Met polymorphism and breast cancer risk: an updated meta-analysis. Diagn Pathol 2012, 7:136. BioMed Central Full Text